# US 2015/0147308 A1 · Compounds for the treatment of neuropsychiatric disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147308 A1
- Document ID: US20150147308A1
- Status: Published application
- Kind: A1
- Application number: 14/612,604
- Filed: 2015-02-03
- Published: 2015-05-28
- Earliest claimed: 2011-04-21
- Assignees: Curemark, LLC
- Applicants: Curemark LLC
- Inventors: Joan M. Fallon; Matthew Heil; James Szigethy; James Fallon
- Web page: https://patentgrep.com/patent/US20150147308A1

## CPC

- A61K 38/54: Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A61K 38/48: acting on peptide bonds (3.4)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/00: Drugs for disorders of the nervous system
- C12Y 301/01: Carboxylic ester hydrolases (3.1.1)
- C12Y 302/01: Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y 304/00: Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of a neuropsychiatric disorder. Also described herein is a method for treating an individual with a neuropsychiatric disorder using digestive enzymes and their derivatives to alleviate the symptoms of neuropsychiatric disorders. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of the neuropsychiatric disorder.

## Claims

### Claim 1

A method for preventing or treating a patient exhibiting one or more symptoms of a neuropsychiatric disorder comprising administering a therapeutically effective amount of a composition comprising digestive enzymes to the individual, wherein one or more symptoms of said neuropsychiatric disorder are treated.

### Claim 2 (depends on 1)

The method of claim 1, wherein the neuropsychiatric disorder is a schizophreniform disorder or a mild anxiety state.

### Claim 3 (depends on 2)

The method of claim 2, wherein said schizophreniform disorder is schizophrenia or psychosis.

### Claim 4

A method for preventing or treating one or more symptoms of schizophrenia or psychosis in a patient administering a therapeutically effective amount of a composition comprising digestive enzymes to the individual, wherein said one or more symptoms of schizophrenia or psychosis are treated.

### Claim 5 (depends on 1)

The method of claim 1, wherein the one or more symptoms are selected from the group consisting of one or more positive symptoms, one or more negative symptoms, one or more symptoms of cognitive impairment, and a combination thereof.

### Claim 6 (depends on 4)

The method of claim 4, wherein the one or more symptoms are selected from the group consisting of one or more positive symptoms, one or more negative symptoms, one or more symptoms of cognitive impairment, and a combination thereof.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1 to 6, wherein said one or more symptoms are reduced in severity or duration by about 2%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 90%, about 95%, or about 100%.

### Claim 8 (depends on 7)

The method of claim 7 wherein said composition is administered until one or more symptoms are partially or completely reduced.

### Claim 9 (depends on 7)

The method of claim 7, wherein said composition is administered 1, 2, 3 or 4 times a day until one or more symptoms are partially or completely reduced.

### Claim 10 (depends on 7)

The method of claim 7, wherein said composition is administered 1, 2, 3 or 4 times a week until one or more symptoms are partially or completely reduced.

### Claim 11 (depends on 7)

The method of claim 7, wherein said method further comprises administering one or more additional agents.

### Claim 12 (depends on 11)

The method of claim 11, wherein said one or more agents is an antipsychotic medication.

### Claim 13 (depends on 12)

The method of claim 12, wherein said antipsychotic medication is a dopamine antagonist or a serotonin antagonist.

### Claim 14 (depends on 7)

The method of any one of claim 7, wherein said method further comprises psychotherapy, vocational rehabilitation, social rehabilitation, or a combination thereof.

### Claim 15 (depends on 5, 6)

The method of claim 5 or 6, wherein the one or more positive symptoms comprise hallucinations, delusions, disorganized thought, disorganized speech, movement disorders, bizarre behavior, or a combination thereof.

### Claim 16 (depends on 5, 6)

The method of claim 5 or 6, wherein the one or more negative symptoms comprise loss of motivation, restricted range of emotional experience and expression, reduced hedonic capacity, affective flattening, alogia, avolition, or a combination thereof.

### Claim 17 (depends on 5, 6)

The method of claim 5 or 6, wherein the one or more symptoms of cognitive impairment comprise poor executive function, inability to use learned information, difficulty paying attention and/or focusing, or a combination thereof.

### Claim 18 (depends on 1, 4)

The method of claim 1 or 4, wherein the composition comprising digestive enzymes comprises amylases, lipases, proteases, or a combination thereof.

### Claim 19 (depends on 18)

The method of claim 18, wherein the composition further comprises chymotrypsin, trypsin, pancreatin, papain, or a combination thereof.

### Claim 20 (depends on 18)

The method of claim 18, wherein the digestive enzymes are derived from a source selected from the group consisting of animal enzymes, plant enzymes, synthetic enzymes, and a combination thereof.

### Claim 21 (depends on 20)

The method of claim 20, wherein the animal enzyme is derived from a mammal.

### Claim 22 (depends on 21)

The method of claim 21, wherein the mammal is a pig.

### Claim 23 (depends on 20)

The method of claim 20, wherein the animal enzyme is derived from a pancreas.

### Claim 24 (depends on 1, 4)

The method of claims 1 or 4, wherein the compositions comprising digestive enzymes are manufactured using a technology selected from the group consisting of enteric coating, lipid encapsulation, direct compression, dry granulation, wet granulation, and a combination thereof.

### Claim 25 (depends on 24)

The method of claim 24, wherein the composition is administered orally.

### Claim 26 (depends on 24)

The method of claim 24, wherein said composition is a dosage formulation selected from the group consisting of pills, tablets, capsules, microcapsules, mini-capsules, time released capsules, mini-tabs, sprinkles, and a combination thereof.

### Claim 27 (depends on 18)

The method of claim 18, wherein the total amount of protease in said composition is from about 10,000 to about 1,500,000 USP units/dose.

### Claim 28 (depends on 27)

The method of claim 27, wherein the total amount of protease is about 5,000; about 7,500; about 10,000; about 15,000; about 20,000; about 25,000; about 30,000; about 40,000; about 50,000; about 65,000; about 75,000; about 100,000; about 140,000; about 140,400; about 150,000; about 200,000; about 250,000; about 300,000; about 350,000; about 400,000; about 450,000; about 465,000; about 500,000; about 550,000; about 600,000; about 650,000; about 700,000; about 750,000; about 800,000; about 850,000; about 900,000; about 950,000; about 1,000,000; about 1,050,000; about 1,100,000; about 1,150,000; about 1,200,000; about 1,250,000; about 1,300,000; about 1,350,000; about 1,400,000; about 1,450,000; or about 1,500,000; about 1,200,000; about 1,250,000; about 1,300,000; about 1,350,000; about 1,400,000; about 1,450,000; or about 1,500,000 U.S.P. units/dose.

### Claim 29 (depends on 18)

The method of claim 18, wherein the total amount of amylase is from about 1,000 to about 15,000,000 U.S.P. units/dose.

### Claim 30 (depends on 29)

The method of claim 29, wherein the total amount of amylase in said composition is about 1,000; about 3,000; about 5,000; about 7,500; about 10,000; about 15,000; about 20,000; about 25,000; about 30,000; about 40,000; about 50,000; about 65,000; about 75,000; about 100,000; about 144,000; about 500,000; about 1,000,000; about 2,000,000; about 3,000,000; about 4,000,000; about 5,000,000; about 6,000,000; about 7,000,000; about 8,000,000; about 9,000,000; about 10,000,000; about 11,000,000; about 12,000,000; about 13,000,000; about 14,000,000; and about 15,000,000 U.S.P. units/dose.

### Claim 31 (depends on 18)

The method of claim 18, wherein the total amount of lipase in said composition is from about 1,500 to about 282,000 U.S.P. units/dose.

### Claim 32 (depends on 31)

The method of claim 31, wherein the total amount of lipase is about 1,500; about 1,880; about 2,000; about 3,000; about 5,000; about 7,500; about 10,000; about 15,000; about 20,000; about 23,000; about 23,040; about 25,000; about 30,000; about 40,000; about 50,000; about 65,000; about 75,000; about 100,000; about 125,000; about 150,000; about 200,000; about 250,000; and about 282,000 U.S.P. units/dose.

### Claim 33

A composition comprising digestive enzymes for use in the prevention or treatment of one or more symptoms of a neuropsychiatric disorder.

### Claim 34 (depends on 33)

The composition of claim 33, wherein the neuropsychiatric disorder is a schizophreniform disorder or a mild anxiety state.

### Claim 35 (depends on 34)

The composition of claim 34, wherein said schizophreniform disorder is schizophrenia or psychosis.

### Claim 36

A composition comprising digestive enzymes for use in the prevention or treatment of one or more symptoms of schizophrenia or psychosis.

### Claim 37 (depends on 33, 36)

The composition of claim 33 or 36, wherein the one or more symptoms are selected from the group consisting of one or more positive symptoms, one or more negative symptoms, one or more symptoms of cognitive impairment, and a combination thereof.

### Claim 38 (depends on 37)

The composition of claim 37, wherein the one or more positive symptoms comprise hallucinations, delusions, disorganized thought, disorganized speech, movement disorders, bizarre behavior, or a combination thereof.

### Claim 39 (depends on 37)

The composition of claim 37, wherein the one or more negative symptoms comprise loss of motivation, restricted range of emotional experience and expression, reduced hedonic capacity, affective flattening, alogia, avolition, or a combination thereof.

### Claim 40 (depends on 37)

The composition of claim 37, wherein the one or more symptoms of cognitive impairment are comprise poor executive function, inability to use learned information, difficulty paying attention and/or focusing, or a combination thereof.

### Claim 41 (depends on 33, 36)

The composition of claim 33 or 36, wherein the composition comprising digestive enzymes comprises amylases, lipases, proteases, or a combination thereof.

### Claim 42 (depends on 41)

The composition of claim 41, wherein the composition further comprises chymotrypsin, trypsin, pancreatin, papain, and a combination thereof.

### Claim 43 (depends on 33, 36)

The composition of claim 33 or 36, wherein the digestive enzymes are derived from a source selected from the group consisting of animal enzymes, plant enzymes, synthetic enzymes, and a combination thereof.

### Claim 44 (depends on 43)

The composition of claim 43, wherein the animal enzyme is derived from a mammal.

### Claim 45 (depends on 44)

The composition of claim 44, wherein the mammal is a pig.

### Claim 46 (depends on 43)

The composition of claim 43, wherein the animal enzyme is derived from a pancreas.

### Claim 47 (depends on 33, 36)

The composition of claim 33 or 36, wherein the compositions comprising digestive enzymes are manufactured using a technology selected from the group consisting of enteric coating, lipid encapsulation, direct compression, dry granulation, wet granulation, and a combination thereof.

### Claim 48 (depends on 47)

The composition of claim 47, wherein the composition is formulated for oral administration.

### Claim 49 (depends on 47)

The composition of claim 47, wherein said composition is a dosage formulation selected from the group consisting of pills, tablets, capsules, microcapsules, mini-capsules, time released capsules, mini-tabs, sprinkles, and a combination thereof.

### Claim 50 (depends on 41)

The composition of claim 41, wherein the total amount of protease in said composition is from about 10,000 to about 1,500,000 USP units/dose.

### Claim 51 (depends on 50)

The composition of claim 50, wherein the total amount of protease is about 5,000; about 7,500; about 10,000; about 15,000; about 20,000; about 25,000; about 30,000; about 40,000; about 50,000; about 65,000; about 75,000; about 100,000; about 140,000; about 140,400; about 150,000; about 200,000; about 250,000; about 300,000; about 350,000; about 400,000; about 450,000; about 465,000; about 500,000; about 550,000; about 600,000; about 650,000; about 700,000; about 750,000; about 800,000; about 850,000; about 900,000; about 950,000; about 1,000,000; about 1,050,000; about 1,100,000; about 1,150,000; about 1,200,000; about 1,250,000; about 1,300,000; about 1,350,000; about 1,400,000; about 1,450,000; or about 1,500,000; about 1,200,000; about 1,250,000; about 1,300,000; about 1,350,000; about 1,400,000; about 1,450,000; or about 1,500,000 U.S.P. units/dose.

### Claim 52 (depends on 41)

The composition of claim 41, wherein the total amount of amylase is from about 1,000 to about 15,000,000 U.S.P. units/dose.

### Claim 53 (depends on 52)

The composition of claim 52, wherein the total amount of amylase in said composition is about 1,000; about 3,000; about 5,000; about 7,500; about 10,000; about 15,000; about 20,000; about 25,000; about 30,000; about 40,000; about 50,000; about 65,000; about 75,000; about 100,000; about 144,000; about 500,000; about 1,000,000; about 2,000,000; about 3,000,000; about 4,000,000; about 5,000,000; about 6,000,000; about 7,000,000; about 8,000,000; about 9,000,000; about 10,000,000; about 11,000,000; about 12,000,000; about 13,000,000; about 14,000,000; and about 15,000,000 U.S.P. units/dose.

### Claim 54 (depends on 41)

The composition of claim 41, wherein the total amount of lipase in said composition is from about 1,500 to about 282,000 U.S.P. units/dose.

### Claim 55 (depends on 54)

The composition of claim 54, wherein the total amount of lipase is about 1,500; about 1,880; about 2,000; about 3,000; about 5,000; about 7,500; about 10,000; about 15,000; about 20,000; about 20,000; about 23,000; about 23,040; about 25,000; about 25,000; about 30,000; about 40,000; about 50,000; about 65,000; about 75,000; about 100,000; about 125,000; about 150,000; about 200,000; about 250,000; and about 282,000 U.S.P. units/dose.

### Claim 56 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

Use of a composition of any one of claims 33-55 in the formulation of a medicament for the treatment of one or more symptoms of a neuropsychiatric disorder.

### Claim 57 (depends on 56)

The use of claim 56, wherein the neuropsychiatric disorder is a schizophreniform disorder or a mild anxiety state.

### Claim 58 (depends on 57)

The use of claim 57, wherein said schizophreniform disorder is schizophrenia or psychosis.

### Claim 59 (depends on 56)

The use of claim 56, wherein the one or more symptoms are selected from the group consisting of one or more positive symptoms, one or more negative symptoms, one or more symptoms of cognitive impairment, and a combination thereof.

### Claim 60 (depends on 59)

The use of claim 59, wherein the one or more positive comprise hallucinations, delusions, disorganized thought, disorganized speech, movement disorders, bizarre behavior, or a combination thereof.

### Claim 61 (depends on 59)

The use of claim 59, wherein the one or more negative symptoms comprise loss of motivation, restricted range of emotional experience and expression, reduced hedonic capacity, affective flattening, alogia, avolition, or a combination thereof.

### Claim 62 (depends on 59)

The use of claim 59, wherein the one or more symptoms of cognitive impairment comprise poor executive function, inability to use learned information, difficulty paying attention and/or focusing, or a combination thereof.

### Claim 63 (depends on 56)

The use of claim 56, wherein the composition comprising digestive enzymes comprises amylases, lipases, proteases, or a combination thereof.

### Claim 64 (depends on 63)

The use of claim 63, wherein the composition further comprises chymotrypsin, trypsin, pancreatin, papain, and a combination thereof.

### Claim 65 (depends on 56)

The use of claim 56, wherein the digestive enzymes are derived from a source selected from the group consisting of animal enzymes, plant enzymes, synthetic enzymes, and a combination thereof.

### Claim 66 (depends on 65)

The use of claim 65, wherein the animal enzyme is derived from a mammal.

### Claim 67 (depends on 66)

The use of claim 66, wherein the mammal is a pig.

### Claim 68 (depends on 65)

The use of claim 65 wherein the animal enzyme is derived from a pancreas.

### Claim 69 (depends on 56)

The use of claim 56, wherein the compositions comprising digestive enzymes are manufactured using a technology selected from the group consisting of enteric coating, lipid encapsulation, direct compression, dry granulation, wet granulation, and a combination thereof.

### Claim 70 (depends on 69)

The use of claim 69, wherein the composition is formulated for oral administration.

### Claim 71 (depends on 69)

The use of claim 69, wherein said composition is a dosage formulation selected from the group consisting of pills, tablets, capsules, microcapsules, mini-capsules, time released capsules, mini-tabs, sprinkles, and a combination thereof.

### Claim 72 (depends on 63)

The use of claim 63, wherein the total amount of protease in said composition is from about 10,000 to about 1,500,000 USP units/dose.

### Claim 73 (depends on 72)

The use of claim 72, wherein the total amount of protease is about 5,000; about 7,500; about 10,000; about 15,000; about 20,000; about 25,000; about 30,000; about 40,000; about 50,000; about 65,000; about 75,000; about 100,000; about 140,000; about 140,400; about 150,000; about 200,000; about 250,000; about 300,000; about 350,000; about 400,000; about 450,000; about 465,000; about 500,000; about 550,000; about 600,000; about 650,000; about 700,000; about 750,000; about 800,000; about 850,000; about 900,000; about 950,000; about 1,000,000; about 1,050,000; about 1,100,000; about 1,150,000; about 1,200,000; about 1,250,000; about 1,300,000; about 1,350,000; about 1,400,000; about 1,450,000; or about 1,500,000; about 1,200,000; about 1,250,000; about 1,300,000; about 1,350,000; about 1,400,000; about 1,450,000; or about 1,500,000 U.S.P. units/dose.

### Claim 74 (depends on 63)

The use of claim 63, wherein the total amount of amylase is from about 1,000 to about 15,000,000 U.S.P. units/dose.

### Claim 75 (depends on 74)

The use of claim 74, wherein the total amount of amylase in said composition is about 1,000; about 3,000; about 5,000; about 7,500; about 10,000; about 15,000; about 20,000; about 25,000; about 30,000; about 40,000; about 50,000; about 65,000; about 75,000; about 100,000; about 144,000; about 500,000; about 1,000,000; about 2,000,000; about 3,000,000; about 4,000,000; about 5,000,000; about 6,000,000; about 7,000,000; about 8,000,000; about 9,000,000; about 10,000,000; about 11,000,000; about 12,000,000; about 13,000,000; about 14,000,000; and about 15,000,000 U.S.P. units/dose.

### Claim 76 (depends on 63)

The use of claim 63, wherein the total amount of lipase in said composition is from about 1,500 to about 282,000 U.S.P. units/dose.

### Claim 77 (depends on 76)

The use of claim 76, wherein the total amount of lipase is about 1,500; about 1,880; about 2,000; about 3,000; about 5,000; about 7,500; about 10,000; about 15,000; about 20,000; about 20,000; about 23,000; about 23,040; about 25,000; about 25,000; about 30,000; about 40,000; about 50,000; about 65,000; about 75,000; about 100,000; about 125,000; about 150,000; about 200,000; about 250,000; and about 282,000 U.S.P. units/dose.

### Claim 78 (depends on 56)

The use of claim 56, wherein said one or more symptoms are reduced in severity or duration by about 2%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 90%, about 95%, or about 100%.

### Claim 79 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

Use of a composition of any one of claims 33-55 in the formulation of a medicament for the treatment of one or more symptoms of schizophrenia or psychosis.

### Claim 80 (depends on 79)

The use of claim 79, wherein the one or more symptoms are selected from the group consisting of one or more positive symptoms, one or more negative symptoms, one or more symptoms of cognitive impairment, and a combination thereof.

### Claim 81 (depends on 80)

The use of claim 80, wherein the one or more positive comprise hallucinations, delusions, disorganized thought, disorganized speech, movement disorders, bizarre behavior, or a combination thereof.

### Claim 82 (depends on 80)

The use of claim 80, wherein the one or more negative symptoms comprise loss of motivation, restricted range of emotional experience and expression, reduced hedonic capacity, affective flattening, alogia, avolition, or a combination thereof.

### Claim 83 (depends on 80)

The use of claim 80, wherein the one or more symptoms of cognitive impairment comprise poor executive function, inability to use learned information, difficulty paying attention and/or focusing, or a combination thereof.

### Claim 84 (depends on 79)

The use of claim 79, wherein the composition comprising digestive enzymes comprises amylases, lipases, proteases, or a combination thereof.

### Claim 85 (depends on 84)

The use of claim 84, wherein the composition further comprises chymotrypsin, trypsin, pancreatin, papain, and a combination thereof.

### Claim 86 (depends on 79)

The use of claim 79, wherein the digestive enzymes are derived from a source selected from the group consisting of animal enzymes, plant enzymes, synthetic enzymes, and a combination thereof.

### Claim 87 (depends on 86)

The use of claim 86, wherein the animal enzyme is derived from a mammal.

### Claim 88 (depends on 87)

The use of claim 87, wherein the mammal is a pig.

### Claim 89 (depends on 86)

The use of claim 86, wherein the animal enzyme is derived from a pancreas.

### Claim 90 (depends on 79)

The use of claim 79, wherein the compositions comprising digestive enzymes are manufactured using a technology selected from the group consisting of enteric coating, lipid encapsulation, direct compression, dry granulation, wet granulation, and a combination thereof.

### Claim 91 (depends on 90)

The use of claim 90, wherein the composition is administered orally.

### Claim 92 (depends on 90)

The use of claim 90, wherein said composition is a dosage formulation selected from the group consisting of pills, tablets, capsules, microcapsules, mini-capsules, time released capsules, mini-tabs, sprinkles, and a combination thereof.

### Claim 93 (depends on 84)

The use of claim 84, wherein the total amount of protease in said composition is from about 10,000 to about 1,500,000 USP units/dose.

### Claim 94 (depends on 93)

The use of claim 93, wherein the total amount of protease is about 5,000; about 7,500; about 10,000; about 15,000; about 20,000; about 25,000; about 30,000; about 40,000; about 50,000; about 65,000; about 75,000; about 100,000; about 140,000; about 140,400; about 150,000; about 200,000; about 250,000; about 300,000; about 350,000; about 400,000; about 450,000; about 465,000; about 500,000; about 550,000; about 600,000; about 650,000; about 700,000; about 750,000; about 800,000; about 850,000; about 900,000; about 950,000; about 1,000,000; about 1,050,000; about 1,100,000; about 1,150,000; about 1,200,000; about 1,250,000; about 1,300,000; about 1,350,000; about 1,400,000; about 1,450,000; or about 1,500,000; about 1,200,000; about 1,250,000; about 1,300,000; about 1,350,000; about 1,400,000; about 1,450,000; or about 1,500,000 U.S.P. units/dose.

### Claim 95 (depends on 84)

The use of claim 84, wherein the total amount of amylase is from about 1,000 to about 15,000,000 U.S.P. units/dose.

### Claim 96 (depends on 95)

The use of claim 95, wherein the total amount of amylase in said composition is about 1,000; about 3,000; about 5,000; about 7,500; about 10,000; about 15,000; about 20,000; about 25,000; about 30,000; about 40,000; about 50,000; about 65,000; about 75,000; about 100,000; about 144,000; about 500,000; about 1,000,000; about 2,000,000; about 3,000,000; about 4,000,000; about 5,000,000; about 6,000,000; about 7,000,000; about 8,000,000; about 9,000,000; about 10,000,000; about 11,000,000; about 12,000,000; about 13,000,000; about 14,000,000; and about 15,000,000 U.S.P. units/dose.

### Claim 97 (depends on 84)

The use of claim 84, wherein the total amount of lipase in said composition is from about 1,500 to about 282,000 U.S.P. units/dose.

### Claim 98 (depends on 97)

The use of claim 97, wherein the total amount of lipase is about 1,500; about 1,880; about 2,000; about 3,000; about 5,000; about 7,500; about 10,000; about 15,000; about 20,000; about 20,000; about 23,000; about 23,040; about 25,000; about 25,000; about 30,000; about 40,000; about 50,000; about 65,000; about 75,000; about 100,000; about 125,000; about 150,000; about 200,000; about 250,000; and about 282,000 U.S.P. units/dose.

### Claim 99 (depends on 79)

The use of claim 79, wherein said one or more symptoms are reduced in severity or duration by about 2%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 90%, about 95%, or about 100%.
